Literature DB >> 22882226

Understanding why patients with immune thrombocytopenia are deeply divided on splenectomy.

Karen K W Wang1, Cathy Charles, Nancy M Heddle, Emmy Arnold, Laura Molnar, Donald M Arnold.   

Abstract

BACKGROUND: Splenectomy is an effective treatment for chronic immune thrombocytopenia (ITP); however, patients' willingness to accept splenectomy is variable.
OBJECTIVE: To explore why some ITP patients accepted splenectomy when recommended by their physician while others refused.
DESIGN: Qualitative descriptive study using one-to-one, in-depth patient interviews and a team-based approach to thematic analysis.
RESULTS: Of 25 patients interviewed, 15 refused splenectomy and 10 accepted and were awaiting surgery. Themes about the influences on splenectomy decision making that emerged from patient interviews were (i) the perceived impact of ITP on quality of life, (ii) patients' view of splenectomy as a last resort treatment, (iii) patients' interpretations of the rates of treatment success and failure and (iv) a perceived lack of familiarity about ITP. Patients who accepted splenectomy perceived their disease as having a negative impact on their quality of life, whereas patients who refused felt their situation was not severe enough to warrant surgery. Patients developed their own experiential interpretations of the success rates of splenectomy quoted to them. A general lack of awareness of the clinical impact of ITP and its cause was identified by patients as barriers to choosing splenectomy.
CONCLUSIONS: Patients' disease experience, perceptions of the lack of treatment alternatives, interpretations of treatment success and failure rates and a general lack of awareness about ITP influenced treatment choice. This study represents a first step towards contextualizing treatment decision making in ITP, focusing on patient preferences and values.
© 2012 John Wiley & Sons Ltd.

Entities:  

Keywords:  patient preferences; thrombocytopenia; treatment decision making

Mesh:

Year:  2012        PMID: 22882226      PMCID: PMC5060920          DOI: 10.1111/j.1369-7625.2012.00806.x

Source DB:  PubMed          Journal:  Health Expect        ISSN: 1369-6513            Impact factor:   3.377


  24 in total

1.  Treatment decision aids: conceptual issues and future directions.

Authors:  Cathy Charles; Amiram Gafni; Tim Whelan; Mary Ann O'Brien
Journal:  Health Expect       Date:  2005-06       Impact factor: 3.377

Review 2.  Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Authors:  Donald M Arnold; Francesco Dentali; Mark A Crowther; Ralph M Meyer; Richard J Cook; Christopher Sigouin; Graeme A Fraser; Wendy Lim; John G Kelton
Journal:  Ann Intern Med       Date:  2007-01-02       Impact factor: 25.391

3.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

4.  Sample size in qualitative research.

Authors:  M Sandelowski
Journal:  Res Nurs Health       Date:  1995-04       Impact factor: 2.228

5.  Use of qualitative research to analyze patient and clinician decision making in carotid endarterectomy.

Authors:  Josephine Gibson
Journal:  J Vasc Nurs       Date:  2002-06

6.  Health professional and consumer views on involving breast cancer patients in the multidisciplinary discussion of their disease and treatment plan.

Authors:  Phyllis Butow; James D Harrison; Ellis T Choy; Jane M Young; Andrew Spillane; Alison Evans
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

7.  Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study.

Authors:  Reimar W Thomsen; W Marieke Schoonen; Dóra K Farkas; Anders Riis; Jacob Jacobsen; Jon P Fryzek; Henrik Toft Sørensen
Journal:  Ann Intern Med       Date:  2009-10-20       Impact factor: 25.391

8.  "You're perfect for the procedure! Why don't you want it?" Elderly arthritis patients' unwillingness to consider total joint arthroplasty surgery: a qualitative study.

Authors:  Pamela L Hudak; Jocalyn P Clark; Gillian A Hawker; Peter C Coyte; Nizar N Mahomed; Hans J Kreder; James G Wright
Journal:  Med Decis Making       Date:  2002 May-Jun       Impact factor: 2.583

9.  Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.

Authors:  Marta Medeot; Francesco Zaja; Nicola Vianelli; Marta Battista; Michele Baccarani; Francesca Patriarca; Franca Soldano; Miriam Isola; Stefano De Luca; Renato Fanin
Journal:  Eur J Haematol       Date:  2008-05-27       Impact factor: 2.997

10.  Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi).

Authors:  Glyn Elwyn; Annette M O'Connor; Carol Bennett; Robert G Newcombe; Mary Politi; Marie-Anne Durand; Elizabeth Drake; Natalie Joseph-Williams; Sara Khangura; Anton Saarimaki; Stephanie Sivell; Mareike Stiel; Steven J Bernstein; Nananda Col; Angela Coulter; Karen Eden; Martin Härter; Margaret Holmes Rovner; Nora Moumjid; Dawn Stacey; Richard Thomson; Tim Whelan; Trudy van der Weijden; Adrian Edwards
Journal:  PLoS One       Date:  2009-03-04       Impact factor: 3.240

View more
  7 in total

1.  Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.

Authors:  Rachael F Grace; Kristin A Shimano; Rukhmi Bhat; Cindy Neunert; James B Bussel; Robert J Klaassen; Michele P Lambert; Jennifer A Rothman; Vicky R Breakey; Kerry Hege; Carolyn M Bennett; Melissa J Rose; Kristina M Haley; George R Buchanan; Amy Geddis; Adonis Lorenzana; Michael Jeng; Yves D Pastore; Shelley E Crary; Michelle Neier; Ellis J Neufeld; Nolan Neu; Peter W Forbes; Jenny M Despotovic
Journal:  Am J Hematol       Date:  2019-04-29       Impact factor: 10.047

Review 2.  Splenectomy for immune thrombocytopenia: down but not out.

Authors:  Shruti Chaturvedi; Donald M Arnold; Keith R McCrae
Journal:  Blood       Date:  2018-01-02       Impact factor: 22.113

3.  Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.

Authors:  Bahareh Ghadaki; Ishac Nazi; John G Kelton; Donald M Arnold
Journal:  Transfusion       Date:  2013-03-03       Impact factor: 3.157

Review 4.  Positioning new treatments in the management of immune thrombocytopenia.

Authors:  Donald M Arnold
Journal:  Pediatr Blood Cancer       Date:  2012-10-25       Impact factor: 3.167

5.  Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis.

Authors:  Jian-Chun Guo; Yi Zheng; Hai-Tao Chen; Haixia Zhou; Xian-Hui Huang; Li-Ping Zhong; Huai-Bin Zhou; Yu Huang; Dan-Li Xie; Yong-Liang Lou
Journal:  Oncotarget       Date:  2017-12-19

6.  The Efficacy and Safety of Different Dosages of Rituximab for Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.

Authors:  Yu Dong; Ming Yue; Mengjiao Hu
Journal:  Biomed Res Int       Date:  2021-10-06       Impact factor: 3.411

Review 7.  Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia.

Authors:  Jose Perdomo
Journal:  Immunotargets Ther       Date:  2016-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.